WO2007148235A3 - Acides nucléiques apparentés au cancer - Google Patents

Acides nucléiques apparentés au cancer Download PDF

Info

Publication number
WO2007148235A3
WO2007148235A3 PCT/IB2007/003116 IB2007003116W WO2007148235A3 WO 2007148235 A3 WO2007148235 A3 WO 2007148235A3 IB 2007003116 W IB2007003116 W IB 2007003116W WO 2007148235 A3 WO2007148235 A3 WO 2007148235A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acids
cancer
related nucleic
polynucleotides
cancers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2007/003116
Other languages
English (en)
Other versions
WO2007148235A2 (fr
Inventor
Ranit Aharonov
Nitzan Rosenfeld
Hila Benjamin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rosetta Genomics Ltd
Original Assignee
Rosetta Genomics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/418,875 external-priority patent/US7592441B2/en
Priority claimed from US11/418,870 external-priority patent/US7825229B2/en
Priority claimed from US11/418,718 external-priority patent/US20070259349A1/en
Priority claimed from US11/429,720 external-priority patent/US7642348B2/en
Application filed by Rosetta Genomics Ltd filed Critical Rosetta Genomics Ltd
Priority to US12/298,065 priority Critical patent/US20090186353A1/en
Publication of WO2007148235A2 publication Critical patent/WO2007148235A2/fr
Priority to IL195066A priority patent/IL195066A0/en
Anticipated expiration legal-status Critical
Publication of WO2007148235A3 publication Critical patent/WO2007148235A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des polynucléotides associés à des types de cancers spécifiques. Lesdites polynucléotides sont des ARNmi, des précurseurs de l'ARNmi, ainsi que des acides associés. L'invention concerne également des méthodes et des compositions pouvant s'utiliser pour établir des diagnostics, des pronostics, ainsi que le traitement de différents cancers.
PCT/IB2007/003116 2004-10-04 2007-05-04 Acides nucléiques apparentés au cancer Ceased WO2007148235A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/298,065 US20090186353A1 (en) 2004-10-04 2007-05-04 Cancer-related nucleic acids
IL195066A IL195066A0 (en) 2006-05-04 2008-11-03 Cancer-related nucleic acids

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US11/418,718 2006-05-04
US11/418,875 2006-05-04
US11/418,870 2006-05-04
US11/418,875 US7592441B2 (en) 2004-10-04 2006-05-04 Liver cancer-related nucleic acids
US11/418,870 US7825229B2 (en) 2005-03-25 2006-05-04 Lung cancer-related nucleic acids
US11/418,718 US20070259349A1 (en) 2006-05-04 2006-05-04 Bladder cancer-related nucleic acids
US11/429,720 2006-05-08
US11/429,720 US7642348B2 (en) 2004-10-04 2006-05-08 Prostate cancer-related nucleic acids
US82524706P 2006-09-11 2006-09-11
US60/825,247 2006-09-11

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US11/418,875 Continuation-In-Part US7592441B2 (en) 2004-10-04 2006-05-04 Liver cancer-related nucleic acids
US11/429,720 Continuation-In-Part US7642348B2 (en) 2004-10-04 2006-05-08 Prostate cancer-related nucleic acids

Publications (2)

Publication Number Publication Date
WO2007148235A2 WO2007148235A2 (fr) 2007-12-27
WO2007148235A3 true WO2007148235A3 (fr) 2009-04-30

Family

ID=38833834

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/003116 Ceased WO2007148235A2 (fr) 2004-10-04 2007-05-04 Acides nucléiques apparentés au cancer

Country Status (2)

Country Link
IL (1) IL195066A0 (fr)
WO (1) WO2007148235A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10660965B2 (en) 2010-03-29 2020-05-26 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563252B2 (en) 2004-05-14 2013-10-22 Rosetta Genomics Ltd. Methods for distinguishing between lung squamous carcinoma and other non small cell lung cancers
JP2010519899A (ja) * 2007-03-01 2010-06-10 ロゼッタ ゲノミックス エルティーディー． 肺扁平上皮癌とその他の非小細胞肺癌とを見分けるための方法
EP2280078B1 (fr) * 2008-03-27 2016-05-18 Kuroda, Masahiko Marqueur pour la détermination du cancer du sein, méthode d'essai, et kit d'essai
EP2281903B1 (fr) * 2008-04-30 2017-01-04 NEC Corporation PROCÉDÉ D ÉVALUATION DU CANCER UTILISANT LE miRNA MARQUEUR DE CANCER
US9068232B2 (en) * 2008-08-06 2015-06-30 Rosetta Genomics Ltd. Gene expression signature for classification of kidney tumors
WO2010016064A2 (fr) * 2008-08-06 2010-02-11 Rosetta Genomics Ltd. Signature d'expression génique pour la classification de tumeurs de rein
WO2010018563A2 (fr) * 2008-08-12 2010-02-18 Rosetta Genomics Ltd. Compositions et procédés de pronostic d'un lymphome
CN102186998A (zh) * 2008-08-19 2011-09-14 人类遗传学与健康缅因州研究院 微小rna和1型神经纤维瘤病在诊断和治疗中
EP2358902A1 (fr) * 2008-12-10 2011-08-24 Universität Regensburg Compositions et procédés pour le profilage de l'expression de micro-arn de cellules souches cancéreuses
EP2419538B1 (fr) * 2009-04-16 2016-09-14 Padma Arunachalam Procédés et compositions visant à détecter et à différencier de petits arn dans un chemin de maturation d'arn
WO2011014697A1 (fr) 2009-07-31 2011-02-03 The Translational Genomics Research Institute Méthodes d’évaluation du risque de progression d’un cancer
WO2011024157A1 (fr) * 2009-08-23 2011-03-03 Rosetta Genomics Ltd. Séquences d'acides nucléiques liées au cancer
ES2631458T3 (es) 2010-03-04 2017-08-31 Interna Technologies B.V. Molécula de ARNmi definida por su fuente y sus usos terapéuticos en el cáncer asociado a la EMT
WO2011154008A1 (fr) 2010-06-11 2011-12-15 Rigshospitalet Classification de micro-arn de néoplasie folliculaire de la thyroïde
JP5755849B2 (ja) * 2010-07-06 2015-07-29 東レ株式会社 胃がんの補助化学療法感受性判定用組成物又はキット
EP2772550B1 (fr) 2010-11-17 2017-03-29 Interpace Diagnostics, LLC Micro-ARN comme biomarqueurs pour différencier des néoplasmes de thyroïde bénins et malins
WO2012161124A1 (fr) * 2011-05-20 2012-11-29 国立大学法人愛媛大学 Composition contenant un micro arn ou système d'expression associé
ITRM20110685A1 (it) * 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
US20180311270A1 (en) * 2015-10-30 2018-11-01 Norimasa Miura Rna molecule for repairing dna damage

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013901A2 (fr) * 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Composes oligomeres et compositions utilisables pour moduler des petits arn non-codants

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013901A2 (fr) * 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Composes oligomeres et compositions utilisables pour moduler des petits arn non-codants

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10660965B2 (en) 2010-03-29 2020-05-26 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents

Also Published As

Publication number Publication date
IL195066A0 (en) 2011-08-01
WO2007148235A2 (fr) 2007-12-27

Similar Documents

Publication Publication Date Title
WO2007148235A3 (fr) Acides nucléiques apparentés au cancer
WO2009108866A3 (fr) Signatures en micro-arn associées à la cytogénétique et au pronostic dans la leucémie myéloïde aiguë (aml) et leurs utilisations
WO2005111211A3 (fr) Micro-arn et utilisations de ceux-ci
WO2010018563A3 (fr) Compositions et procédés de pronostic d'un lymphome
WO2005116250A3 (fr) Arnmi viraux ou associes aux virus et leur utilisation
WO2009111643A3 (fr) Marqueurs microrna pour la récurrence d’un cancer colorectal
WO2007134210A3 (fr) Méthodes et compositions destinées au diagnostic et au traitement du cancer
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
WO2010099161A8 (fr) Microarn chez les non-fumeurs et méthodes et matières apparentées
WO2008073915A3 (fr) Microarn exprimés de manière différentielle en cas de leucémie et leurs utilisations
WO2008078180A3 (fr) Matériaux et procédés pour la génération de transcrits comprenant des nucléotides modifiés
WO2009108860A8 (fr) Procédés et compositions à base de micro-arn permettant de diagnostiquer, de pronostiquer et de traiter des troubles liés à la prostate
WO2012068400A3 (fr) Micro-arn utilisés comme biomarqueurs pour faire la distinction entre des néoplasmes thyroïdiens bénins et malins
WO2009055773A3 (fr) Méthodes pour identifier une interaction du gène 'fragile histidine triad' (fhit) et utilisations associées
WO2010065630A3 (fr) Compositions et procédés de traitement d'une néoplasie hépatique
ZA200904684B (en) Enzymes for the treatment of lignocellulosics, nucleic acids encoding them and methods for making and using them
WO2008087040A3 (fr) Procédés et acides nucléiques pour analyses des troubles prolifératifs cellulaires
CA2840149C (fr) Methodes et acides nucleiques permettant d'etablir le pronostic d'un sujet atteint de cancer
WO2009036427A3 (fr) Biomarqueurs du cancer de la prostate
WO2008002672A3 (fr) Cibles utilisées pour le diagnostic, le pronostic et la thérapie du cancer
WO2008092099A3 (fr) Compositions et procédés de traitement de malignités hématopoïétiques
EP3019611A4 (fr) Arnsi spécifique de gènes liés au cancer du foie, molécules d'oligo-arn double brin comprenant l'arnsi, et composition de prévention ou de traitement du cancer le comprenant
EP3019612A4 (fr) Arnsi spécifique de gènes lié au cancer du foie, molécules d'oligo-arn double brin comprenant l'arnsi, et composition de prévention ou de traitement du cancer le comprenant
WO2011021177A3 (fr) Compositions et procédés de pronostic et de traitement du cancer de la prostate
EP2322652A8 (fr) MicroARN et leurs utilisations

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12298065

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 07845192

Country of ref document: EP

Kind code of ref document: A2